Patient characteristics associated with concurrent use of thyroid hormone therapy and interfering medications
| Patient characteristics . | Odds ratio (95% CI) . |
|---|---|
| Sex | |
| Male | Ref |
| Female | 1.11 (1.08-1.15) |
| Age | |
| 65-74 | Ref |
| 75-84 | 0.74 (0.73-0.75) |
| ≥ 85 | 0.48 (0.47-0.48) |
| Race | |
| White | Ref |
| Black/African American | 1.25 (1.21-1.28) |
| Othera | 1.05 (1.00-1.09) |
| Unknown | 0.75 (0.73-0.77) |
| Ethnicity | |
| Non-Hispanic | Ref |
| Hispanic | 1.12 (1.09-1.15) |
| Unknown | 0.80 (0.78-0.82) |
| Charlson/Deyo Comorbidity Score | |
| 0 | Ref |
| 1 | 1.52 (1.49-1.56) |
| ≥ 2 | 2.50 (2.45-2.54) |
| Patient characteristics . | Odds ratio (95% CI) . |
|---|---|
| Sex | |
| Male | Ref |
| Female | 1.11 (1.08-1.15) |
| Age | |
| 65-74 | Ref |
| 75-84 | 0.74 (0.73-0.75) |
| ≥ 85 | 0.48 (0.47-0.48) |
| Race | |
| White | Ref |
| Black/African American | 1.25 (1.21-1.28) |
| Othera | 1.05 (1.00-1.09) |
| Unknown | 0.75 (0.73-0.77) |
| Ethnicity | |
| Non-Hispanic | Ref |
| Hispanic | 1.12 (1.09-1.15) |
| Unknown | 0.80 (0.78-0.82) |
| Charlson/Deyo Comorbidity Score | |
| 0 | Ref |
| 1 | 1.52 (1.49-1.56) |
| ≥ 2 | 2.50 (2.45-2.54) |
a“Other” includes Asian, Native Hawaiian/Pacific Islander, American Indian/Alaska Native, and multiracial.
Patient characteristics associated with concurrent use of thyroid hormone therapy and interfering medications
| Patient characteristics . | Odds ratio (95% CI) . |
|---|---|
| Sex | |
| Male | Ref |
| Female | 1.11 (1.08-1.15) |
| Age | |
| 65-74 | Ref |
| 75-84 | 0.74 (0.73-0.75) |
| ≥ 85 | 0.48 (0.47-0.48) |
| Race | |
| White | Ref |
| Black/African American | 1.25 (1.21-1.28) |
| Othera | 1.05 (1.00-1.09) |
| Unknown | 0.75 (0.73-0.77) |
| Ethnicity | |
| Non-Hispanic | Ref |
| Hispanic | 1.12 (1.09-1.15) |
| Unknown | 0.80 (0.78-0.82) |
| Charlson/Deyo Comorbidity Score | |
| 0 | Ref |
| 1 | 1.52 (1.49-1.56) |
| ≥ 2 | 2.50 (2.45-2.54) |
| Patient characteristics . | Odds ratio (95% CI) . |
|---|---|
| Sex | |
| Male | Ref |
| Female | 1.11 (1.08-1.15) |
| Age | |
| 65-74 | Ref |
| 75-84 | 0.74 (0.73-0.75) |
| ≥ 85 | 0.48 (0.47-0.48) |
| Race | |
| White | Ref |
| Black/African American | 1.25 (1.21-1.28) |
| Othera | 1.05 (1.00-1.09) |
| Unknown | 0.75 (0.73-0.77) |
| Ethnicity | |
| Non-Hispanic | Ref |
| Hispanic | 1.12 (1.09-1.15) |
| Unknown | 0.80 (0.78-0.82) |
| Charlson/Deyo Comorbidity Score | |
| 0 | Ref |
| 1 | 1.52 (1.49-1.56) |
| ≥ 2 | 2.50 (2.45-2.54) |
a“Other” includes Asian, Native Hawaiian/Pacific Islander, American Indian/Alaska Native, and multiracial.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
